Name and surname:
|
MUDr. Ján Jurenka
|
Document type:
|
Research/art/teacher profile of a person
|
The name of the university:
|
Comenius University Bratislava
|
The seat of the university:
|
Šafárikovo námestie 6, 818 06 Bratislava
|
III.a - Occupation-position | III.b - Institution | III.c - Duration |
---|---|---|
University teacher | Faculty of Medicine, Comenius University in Bratislava | 2019 |
V.1.a - Name of the profile course | V.1.b - Study programme | V.1.c - Degree | V.1.d - Field of study |
---|---|---|---|
infectology | general medicine | II | general medicine |
Dababseh MMO, Sabaka P, Duraníková O, et al. Delayed Antibody Response in the Acute Phase of Infection Is Associated with a Lower Mental Component of Quality of Life in Survivors of Severe and Critical COVID-19. J Clin Med. 2024;13(7):1938. Published 2024 Mar 27. doi:10.3390/jcm13071938 (2022: IF: 3.9, Q2 JCR, Q1 SJR)
Jurenka J, Nagyová A, Dababseh M, et al. Anti-SARS-CoV-2 Antibody Status at the Time of Hospital Admission and the Prognosis of Patients with COVID-19: A Prospective Observational Study. Infect Dis Rep. 2022;14(6):1004-1016. Published 2022 Dec 11. doi:10.3390/idr14060100 (2022: IF 3.2, Q3 JCR, Q2 SJR)
Mihalov P, Hodosy J, Koščálová A, Čaprnda M, Kachlíková M, Jurenka J, Bendžala M, Sabaka P. Antimicrobial Therapy as a Risk Factor of Multidrug-Resistant Acinetobacter Infection in COVID-19 Patients Admitted to the Intensive Care Unit. Can J Infect Dis Med Microbiol. 2023 Sep 14;2023:4951273. doi: 10.1155/2023/4951273. PMID: 37745269; PMCID: PMC10513818. (2021: IF 2.585, Q3 JCR, Q3 SJR).
Jurenka J, Nagyová A, Dababseh M, et al. Anti-SARS-CoV-2 Antibody Status at the Time of Hospital Admission and the Prognosis of Patients with COVID-19: A Prospective Observational Study. Infect Dis Rep. 2022;14(6):1004-1016. Published 2022 Dec 11. doi:10.3390/idr14060100 (2022: IF 3.2, Q3 JCR, Q2 SJR)
Dababseh MMO, Sabaka P, Duraníková O, et al. Delayed Antibody Response in the Acute Phase of Infection Is Associated with a Lower Mental Component of Quality of Life in Survivors of Severe and Critical COVID-19. J Clin Med. 2024;13(7):1938. Published 2024 Mar 27. doi:10.3390/jcm13071938 (2022: IF: 3.9, Q2 JCR, Q1 SJR)
Mihalov P, Hodosy J, Koščálová A, Čaprnda M, Kachlíková M, Jurenka J, Bendžala M, Sabaka P. Antimicrobial Therapy as a Risk Factor of Multidrug-Resistant Acinetobacter Infection in COVID-19 Patients Admitted to the Intensive Care Unit. Can J Infect Dis Med Microbiol. 2023 Sep 14;2023:4951273. doi: 10.1155/2023/4951273. PMID: 37745269; PMCID: PMC10513818. (2021: IF 2.585, Q3 JCR, Q3 SJR).